Improving Patient Outcomes in Chronic Myeloid Leukemia: Monitoring and Managing Response and Resistance

References


Jabbour E, Kantarjian M, Shan J, et al. The achievement of a 3-month complete cytogenetic response (3-mo CCyR) to second generation (2nd) tyrosine kinase inhibitors (TKI) post imatinib failure is the only predictive factor for event-free (EFS) and overall survival (OS) *Blood.* 2010;116:abstract 2289.


Nazha A, Kantarjian HM, Jain P, et al. Disease patterns for patients (pts) with chronic myeloid leukemia (CML) that have BCR-ABL transcript levels > 10% at 3 month of therapy with tyrosine kinase inhibitors (TKIs). Blood. 2012;120:abstract 3757.


Paschka P, Müller MC, Merx K, et al. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission. Leukemia. 2003;17(9):1687-1694.


